**Description**

**A FORMULATION INTENDED TO DISPLAY AN ANTI-CARCINOGENIC EFFECT BY ITS NF-KAPPA B SUPPRESSION CAPABILITY**

**Field of Invention**

The present invention herewith discloses a formulation developed to display anti-carcinogenic effect by its nf-kappa b suppression capability.

**Background of the Related Technology**

At present it is known that NF-kappa B (NF-κB, Nuclear Factor kappa B), is a transcription factor found in all cell types. It is in an inactive state inside the cytoplasm. When it becomes active, it is carried to the nucleus. There are five types of it: NF-κB1, NF-κB2, RelA (p65), RelB and c-Rel. It is believed that NF-kappa B has some impact in development of certain auto-immune diseases (e.g. ulcerative colitis, Crohn’s Disease).

In state of art technology, invention no “EP1499729B1", with title “NF-kappa b Inducing Enzyme Derivatives, Their Preparation and Use” and under classification number “A61K 31/711" discloses methods for using NIK and related molecules as well as some similar new molecules, for modulation of signal activities controlled by cytokines.

Again invention no “EP2064228B1", with title “Synthetic Peptide Amides”, discloses kappa opioid receptor’s synthetic amide ligands and specifically the kappa opioid receptor agonists that is characterized by its low penetration into the brain and low P450 CYP inhibition. The synthetic peptide amides of the invention referred, is in the structure of formula (I). Pharmaceutical compositions containing these compounds are useful in prevention and treatment of pain and inflammation related to various diseases and disorders. Such treatable pains include neuropathic pain and hyperalgesia. Inflammation related to cases like IBD and IBS, ocular and otic inflammation and other disorders and irregularities like prarifis, edema, hyponatremia, hypokalemia, ileus, cough and glaucoma can be prevented or treated by using the pharmaceutical compositions of the invention referred.

Again invention no “EP1830827B1", with title “Perfluorocarbon Liquids to Eliminate Carcinogenic Substances” and under classification number “A61K 31/02" describes inert perflourocarbon liquids which are biologically compliant and can eliminate carcinogenic substances from the cells and thus reduce the transformation risk in cancer cells. This referred invention reduces clustering of carcinogenic substances and thus can be used as prophylactic drugs in induced cancer cell transformation and cancer risk reduction. Such liquids can be used as drugs that can be administered to any organ in the body and such an application will reduce the clustering of carcinogenic chemicals in the related cell and thus can be used in reducing the risk of various cancers that develop via chemical carcinogenesis. Such cancers include various types of lung cancer, stomach cancer, rectal cancer and skin cancer.

To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a formulation that will display anti-carcinogenic effect by its nf-kappa b suppression capability.

**Objective of the Invention**

To overcome the disadvantages experienced in state of art technology;

* One objective of the invention is to suppress nf-kappa B expression.
* One other objective of the invention is to suppress, interleukin 6 expression.

The present invention which is aimed to achieve the above-mentioned advantages, is intended to develop a formulation that will display anti-carcinogenic effect by its nf-kappa b suppression capability and is a formulation that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-*O*-β-D-glucopyranosyl-β-D-trihydroxypyranoside, 3,7-bis(2-hydroxyethyl)-8-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one.

Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith.

**Detailed Description of the Invention**

The present invention herewith is a formulation developed to display anti-carcinogenic effect by its NF-KAPPAB suppression capability. Referred formulation suppresses nf-kappa B expression and suppresses interleukin 6 expression.

Interleukin is a group of cytokines, which are hidden signaling molecules, expressed by the white blood cells lymphocytes, where they were first discovered. Their name is derived from -leukin from lymphocytes and from Inter- meaning communication.

The formulation of the invention presented herewith contains; (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-*O*-β-D-glucopyranosyl-β-D-trihydroxy pyranoside, 3,7-bis(2-hydroxyethyl)-8-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one .

The referred formulation is formed by mixing the above-mentioned components at below percentages by weight;

* 1-99% of (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-*O*-β-D-glucopyranosyl-β-D-trihydroxypyranoside,
* 99-1% of 3,7-bis(2-hydroxyethyl)-8-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one.

Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof.

The present invention at the same time discloses using the above-referred formulation to display anti-carcinogenic effect by its nf-kappa b suppression capability and manufacturing it for such purpose.

 **CLAIMS**

1. A formulation that displays anti-carcinogenic effect by its nf-kappa b suppression capability and which consists of combining the components selected from the group; (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-*O*-β-D-glucopyranosyl-β-D-trihydroxypyranoside, 3,7-bis(2-hydroxyethyl)-8-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one in a single form or in combinations thereof.
2. The formulation of Claim 1 which is characterized by containing  1-99% of (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-*O*-β-D-glucopyranosyl-β-D-trihydroxypyranoside by weight.
3. The formulation of Claim 1 which is characterized by containing 99-1% of 3,7-bis(2-hydroxyethyl)-8-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one by weight.
4. Using the compositions obtained by selecting singly or in combination of components from the group of; (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-*O*-β-D-glucopyranosyl-β-D-trihydroxypyranoside, 3,7-bis(2-hydroxyethyl)-8-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one from any one as given in Claims 2-3 in manufacturing the formulation that displays anti-carcinogenic effect by its nf-kappa b suppression capability.

**SUMMARY**

**A FORMULATION INTENDED TO HAVE AN ANTI-CARCINOGENIC EFFECT BY İTS NF-KAPPA B SUPPRESSION CAPABILITY**

The present invention herewith is a formulation developed to display anti-carcinogenic effect by its NF-KAPPAB suppression capability. Referred formulation suppresses nf-kappa B expression and suppresses interleukin 6 expression.

There are no illustrations.